EUVIMEDEUVIMED entdecken
Crossref

Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR ‐ TKIs in Real‐World Patients With Advanced Renal Cell Carcinoma

Hiroki Ishihara, Nanaka Katsurayama, Yuki Nemoto, Shinsuke Mizoguchi, Takayuki Nakayama, Hironori Fukuda, Hiroaki Shimmura, Yasunobu Hashimoto, Kazuhiko Yoshida, Junpei Iizuka, Tsunenori Kondo, Toshio Takagi iD

International Journal of Urology · 2026-03 · 33 (3)

DOI: 10.1111/iju.70444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 25.03.2026. Verfasst von Hiroki Ishihara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data are available on the midterm outcomes of combination therapy with immune checkpoint inhibitors and VEGFR‐TKIs (IO‐TKI) for advanced renal cell carcinoma (RCC) in real‐world settings.

Methods

We retrospectively evaluated data from 68 patients who received lenvatinib plus pembrolizumab ( n = 14), cabozantinib plus nivolumab ( n = 20), pembrolizumab plus axitinib ( n = 23), or avelumab plus axitinib ( n = 11) as first‐line therapy for advanced RCC. All patients initiated IO‐TKI at least 3 years before the data‐cutoff, ensuring a potentially minimum follow‐up of 3 years. Effectiveness and safety profiles were assessed.

Results

During a median follow‐up of 32.7 months, the median progression‐free survival (PFS) and overall survival (OS) were 19.9 and 46.7 months, respectively. The objective response rate was 57%. In subgroup analysis, histology was associated with survival outcomes; median PFS (23.0 vs. 13.8 months, p = 0.0503) and OS (not reached vs. 37.4 months, p = 0.0016) were longer in patients with clear‐cell RCC than in those with non‐clear‐cell RCC. Regarding safety, Grade 3 adverse events occurred in 44 patients (65%). Treatment discontinuation of both drugs was required in 14 patients (21%), and discontinuation of one drug in 21 patients (31%). High‐dose glucocorticoids (≥ 40 mg prednisone/day) were required in 10 patients (15%).

Conclusion

With a minimum of 3 years of follow‐up, IO‐TKI demonstrated feasible effectiveness and manageable safety in patients with advanced RCC in the real world. More effective treatment strategies and novel therapeutic targets are needed for patients with non‐clear‐cell RCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsProtein Kinase InhibitorsHumansFemaleMaleRetrospective StudiesAgedAntibodies, Monoclonal, HumanizedMiddle AgedProgression-Free SurvivalPhenylurea CompoundsAnilidesNivolumabAxitinibQuinolinesPyridinesTreatment OutcomeReceptors, Vascular Endothelial Growth FactorAged, 80 and overAdult

Stichwörter der Autor:innen

PD‐1PD‐L1immunotherapyimmuno‐oncologytargeted therapy

Substanzen

Immune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedProtein Kinase InhibitorsPhenylurea CompoundspembrolizumabAnilidesNivolumabcabozantinibavelumabAxitinib

Autor:innen und Institutionen

  • Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.
  • Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
  • Department of Urology, Jyoban Hospital, Fukushima, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Saitama, Japan.

ORCID-Profile: Toshio Takagi

Zitieren

APA

Ishihara, H., Katsurayama, N., Nemoto, Y., Mizoguchi, S., Nakayama, T., Fukuda, H., Shimmura, H., Hashimoto, Y., Yoshida, K., Iizuka, J., Kondo, T., & Takagi, T. (2026). Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR ‐ TKIs in Real‐World Patients With Advanced Renal Cell Carcinoma. International Journal of Urology, 33(3). https://doi.org/10.1111/iju.70444

Vancouver

Ishihara H, Katsurayama N, Nemoto Y, Mizoguchi S, Nakayama T, Fukuda H, et al. Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR ‐ TKIs in Real‐World Patients With Advanced Renal Cell Carcinoma. International Journal of Urology. 2026;33(3). doi:10.1111/iju.70444

BibTeX
@article{Ishihara2026,
  author = {Ishihara, Hiroki and Katsurayama, Nanaka and Nemoto, Yuki and Mizoguchi, Shinsuke and Nakayama, Takayuki and Fukuda, Hironori and Shimmura, Hiroaki and Hashimoto, Yasunobu and Yoshida, Kazuhiko and Iizuka, Junpei and Kondo, Tsunenori and Takagi, Toshio},
  title = {Midterm Outcomes of Combination Therapy With Immune Checkpoint Inhibitors and VEGFR ‐ TKIs in Real‐World Patients With Advanced Renal Cell Carcinoma},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/iju.70444}
}
Kostenlos starten →